申请人:Celltech Therapeutics, Limited
公开号:US06235746B1
公开(公告)日:2001-05-22
Compounds of general formula (1) are described:
wherein R1 is a hydrogen or halogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group or a group selected from hydroxyl (—OH), substituted hydroxyl, thiol (—SH), substituted thiol, amino (—NH2), or substituted amino;
R2 and R3, which may be the same or different, is each an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group;
R4 is a hydrogen atom or a straight or branched chain alkyl group;
R5 is a hydrogen atom or an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group;
R6 is a hydrogen or halogen atom or an amino (—NH2), substituted amino, nitro, carboxyl (—CO2H) or esterified carboxyl group or a group —X1—R6a where X1 is a direct bond or a linker atom or group and R6a is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group;
X is a direct bond or a linker atom or group;
R7 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof.
The compounds are selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role.
描述了一般式(1)的化合物:其中R1是氢或卤素原子,或者是可选取代的直链或支链烷基,烯基或炔基或者是从羟基(-OH),取代羟基,硫醇(-SH),取代硫醇,氨基(-NH2)或取代氨基中选择的基团;R2和R3可能相同也可能不同,分别是可选取代的直链或支链烷基,烯基或炔基;R4是氢原子或直链或支链烷基;R5是氢原子或可选取代的直链或支链烷基,烯基或炔基;R6是氢或卤素原子或氨基(-NH2),取代氨基,硝基,羧基(-CO2H)或酯化羧基基团或者是基团-X1-R6a,其中X1是直接键或连接原子或基团,R6a是可选取代的直链或支链烷基,烯基或炔基;X是直接键或连接原子或基团;R7是可选取代的脂肪族,环脂肪族,杂原子脂肪族,杂环脂肪族,芳香族或杂芳香族基团;以及其盐,溶剂化合物,水合物和N-氧化物。这些化合物是选择性蛋白激酶抑制剂,特别是激酶p56lck,p59fyn,ZAP-70和蛋白激酶C,并可用于预防和治疗免疫性疾病,过度增殖性疾病以及其他不适当的蛋白激酶作用被认为具有作用的疾病。